Germany-based Thermosome, a drug development company specializing in targeted tumor therapies, has named Frank Hermann as chief medical officer (CMO).
The appointment has been made to support the development of Thermosome's clinical candidate, THE001.
"There is a significant unmet medical need for targeted tumor therapies that are designed to eliminate soft tissue sarcomas with improved precision and potency"Dr Hermann is a clinical oncology professional with extensive experience in medical affairs, clinical research, and development. Before joining Thermosome, he was vice president, clinical development at immuno-oncology company CatalYm.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze